SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 254,959 shares, a growth of 20.3% from the March 15th total of 211,974 shares. Based on an average trading volume of 96,355 shares, the days-to-cover ratio is presently 2.6 days. Currently, 0.4% of the company’s stock are short sold.

Insider Buying and Selling

In related news, CEO Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00. Following the sale, the chief executive officer directly owned 3,646,967 shares in the company, valued at $18,234,835. This trade represents a 0.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 181,300 shares of company stock worth $880,323. 4.88% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SOPH. Alta Wealth Advisors LLC bought a new position in SOPHiA GENETICS during the 3rd quarter valued at $6,708,000. Susquehanna International Group LLP acquired a new stake in shares of SOPHiA GENETICS during the third quarter worth $88,000. XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter worth about $55,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter worth about $54,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth about $49,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH traded up $0.16 on Friday, hitting $5.28. The company’s stock had a trading volume of 94,798 shares, compared to its average volume of 179,935. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $5.70. The company has a market capitalization of $361.42 million, a price-to-earnings ratio of -10.36 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The stock has a 50 day moving average of $4.75 and a 200-day moving average of $4.72.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. As a group, research analysts predict that SOPHiA GENETICS will post -0.96 EPS for the current year.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at an NCI-designated cancer center; this enhances U.S. credibility and could drive recurring platform volume from a major health system. Read More.
• Positive Sentiment: Sector validation — press coverage on Mount Sinai using AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption tailwinds and future revenue potential. Read More.
• Positive Sentiment: Analyst support — select firms (BTIG, Guggenheim) have raised price targets and maintain buy ratings, providing upside reference points versus current levels and helping investor sentiment.
• Neutral Sentiment: Insider sales disclosed — multiple insiders (CEO Jurgi Camblong, President Ross Muken, and others) sold shares in mid‑April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which lessens governance concern but increases share supply. Read More.
• Negative Sentiment: Earnings and profitability pressure — SOPH reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a large negative ROE; analysts still expect FY losses (~-0.96 EPS), which can cap valuation and limit multiple expansion until a clear path to profitability is shown. Read More.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Guggenheim lifted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.